<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40137">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840423</url>
  </required_header>
  <id_info>
    <org_study_id>3112001</org_study_id>
    <nct_id>NCT01840423</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers</brief_title>
  <acronym>NOCIFIM</acronym>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-104: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of escalating doses of
      ODM-104 when given to healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into two parts. Part one is a crossover study where healthy volunteers
      will receive two doses of ODM-104 and one dose of placebo. Part II of the study is a
      multiple ascending dose parallel group study where healthy volunteers will receive ODM-104
      three times daily for seven days. Healthy volunteers taking part in Part II of the study
      will also receive levo/carbidopa and entacapone four times daily on day 1 and levo/carbidopa
      in addition to ODM-104 on day 9. The study will also look at the pharmacokinetic(how the
      body handles the drug) and pharmacodynamics (how the drug affects the body) of ODM-104.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>Erythrocyte COMT inhibition.</measure>
    <time_frame>0, 0.16, 0.33, 0.5, 0.75,1.0,1.5, 2, 3, 4, 6, 10, 16, 24h post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximal COMT inhibition and area under the COMT inhibition curve AUCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>0, 0.16, 0.33, 0.5, 0.75, 1, 1.5, 2, 2, 4, 6, 10, 16, 24h post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC under the plasma concentration curve</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ODM-104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral capsules given once daily for one day or three times daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>entacapone + levodopa/carbidopa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-104</intervention_name>
    <description>ODM-104</description>
    <arm_group_label>ODM-104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entacapone</intervention_name>
    <description>entacapone + levodopa/carbidopa</description>
    <arm_group_label>entacapone + levodopa/carbidopa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa/carbidopa</intervention_name>
    <description>entacapone + levodopa/carbidopa</description>
    <arm_group_label>entacapone + levodopa/carbidopa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects aged between 18 and 45 years

          -  BMI 18-30 kg/m2

          -  Weight 55-95kg

          -  Written informed consent

          -  Good General Health

        Exclusion Criteria:

          -  Vulnerable subjects

          -  Veins unsuitable for repeated venipuncture

          -  Evidence of clinically significant cardiovascular, renal, hepatic, hematological, Gi,
             pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disorder

          -  History of or positive test for drug abuse

          -  Any condition requiring regular concomitant medication

          -  Blood donation or significant loss of blood within 2 months prior to screening

          -  Abnormal 12 lead ECG finding of clinical relevance - HR &lt;50bpm or &gt;90bpm after 10
             minutes in a supine position

          -  Systolic blood pressure &lt;90mmHg or &gt;140mmHg after 10 minutes in a supine position

          -  Diastolic blood pressure &lt;50mmHg or &gt;90mmHg after 10 minutes in a supine position

          -  Abnormal 24 hour Holter recording of clinical relevance at screening

          -  Any abnormal laboratory value, vital signs or physical examination causing a health
             risk to the volunteer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainard Fuhr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel International GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>angela ruck, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rainard Fuhr, MD</last_name>
    <phone>+49 30 30685</phone>
    <phone_ext>361</phone_ext>
    <email>rainard.fuhr@parexel.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regina Boensch, PhD</last_name>
    <phone>+49 30 30685</phone>
    <phone_ext>5825</phone_ext>
    <email>regina.boensch@parexel.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainard Fuhr, MD</last_name>
      <phone>+ 49 30 30685 361</phone>
      <email>rainard.fuhr@parexel.com</email>
    </contact>
    <investigator>
      <last_name>Rainard Fuhr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>April 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First in man study</keyword>
  <keyword>Volunteer study</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Entacapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
